CAR T-cell therapy for advanced lymphoma – Fred Hutch researchers including Drs. Stanley Riddell, David Maloney and Cameron Turtle are contributing landmark discoveries about how to engineer immune cells called T cells for cancer therapy. Their focus is on developing and testing CAR T cells (CAR stands for chimeric antigen receptor), which are genetically reprogrammed to target the patient's disease. Results from a CAR T-cell therapy clinical trial that included patients with advanced non-Hodgkin lymphoma have shown promising, even dramatic responses. By selecting the best T cells from each patient and carefully controlling the composition of treatments, our scientists are continuing to achieve more predictable, consistent and lasting therapeutic effects in patients. Learn more >
Making immunotherapy safer – While CAR T-cell therapy can harness the immune system to fight cancer, it also can produce toxic, potentially life-threatening side effects. Fred Hutch researchers have identified potential biomarkers associated with the development of such side effects. They also have created computer algorithms to identify the rare patients whose symptoms are most likely to turn deadly. The researchers anticipate that their work could eventually help reduce the risk of the severe treatment-related side effects for patients who receive CAR T-cell therapies in the future. Learn more >
Developing therapies for follicular lymphoma – Dr. Oliver Press and colleagues developed a therapy for follicular lymphoma, a slow-growing form of non-Hodgkin lymphoma that is usually diagnosed at an advanced, incurable stage. The treatment consists of six cycles of a four-drug chemotherapy regimen for lymphoma, followed by treatment with Bexxar, the trade name for a radioactively-tagged antibody, to destroy cancer cells. Learn more >
Spearheading new medications — Our researchers pioneered use of an antibody to treat some forms of non-Hodgkin lymphoma. Work by Dr. David Maloney was instrumental in developing Rituximab, the first medication of its kind approved in the United States for treating malignant disease—and the one of the best-selling anticancer drugs. About half of patients treated with this drug see their cancers go into remission.
Listen to a webcast with Dr. David Maloney >
Making treatments less toxic — Dr. Ajay Gopal and colleagues have discovered new ways to target treatment for non-Hodgkin lymphoma that reduces damage in healthy tissue. Using radioactively tagged proteins that bind to tumors, physicians can deliver very high doses of radiation that minimize damage to surrounding healthy cells. The treatment is particulary safer and more effective for elderly patients. Learn more >
Pioneering bone marrow transplantation – Led by Nobel Prize recipient Dr. E. Donnall Thomas, Fred Hutch researchers have transformed bone marrow transplantation into standard treatment for leukemia, lymphoma and other blood cancers. The procedure is one of cancer treatment's biggest success stories and has saved the lives of hundreds of thousands of patients. Learn more >
Reducing radiation in transplants — By minimizing the radiation patients receive before their bone marrow transplant, Hutch researchers have helped make this life-saving procedure less available to more patients, with similar results as traditional bone marrow transplants. Learn more >